ACORQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACORQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Acorda Therapeutics's Trailing 12-Month Free Cash Flow is $-27.15 Mil, and Market Cap is $0.02 Mil. Therefore, Acorda Therapeutics's FCF Yield % for today is 0.00%.
The historical rank and industry rank for Acorda Therapeutics's FCF Yield % or its related term are showing as below:
Acorda Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was -99.49%.
The historical data trend for Acorda Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acorda Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
FCF Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
-224.36 | -166.60 | -131.27 | -112.85 | -76.02 |
Acorda Therapeutics Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
FCF Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-286.07 | 163.46 | -64.41 | -492.08 | - |
For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Acorda Therapeutics's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Acorda Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -14.248 | / | 18.74178 | |
= | -76.02% |
Acorda Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -20.185 | * | 4 | / | 16.408062 | |
= | -492.08% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acorda Therapeutics FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Acorda Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas M. Burns | director | 2910 SEVENTH STREET, BERKELEY CA 94710 |
Ron Cohen | officer: CEO and President | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
John Varian | director | ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Michael A Gesser | officer: Chief Financial Officer | 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Neil S. Belloff | officer: General Counsel | 11 RADNOR LANE, MAHOPAC NY 10541 |
Kerry M Clem | officer: Chief Commercial Officer | 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Robert Morales | officer: Interim PAO & PFO | 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Jane Wasman | officer: Exec V Pres, Gen Cnsl & Sec | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Lauren M Sabella | officer: Exec. VP-Commercial Dvlpmnt | C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
David Lawrence | officer: Chief Financial Officer | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Scopia Capital Management Lp | 10 percent owner | 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019 |
Lorin Randall | director | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Burkhard Blank | officer: Chief Medical Officer | C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Scopia Management, Inc. | 10 percent owner | 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019 |
Matthew Sirovich | 10 percent owner | C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123 |
From GuruFocus
By GuruFocus Research • 02-06-2024
By Business Wire • 04-03-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.